Tags : Pancreas

Astellas Signs an Exclusive License Agreement with Pandion to Deliver

Shots: Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while […]Read More